Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Curis, Inc. (CRIS)

AIM ImmunoTech Inc. and Curis, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Curis, Inc. are of similar size ($6.1M and $5.7M). Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −21.5%. Curis, Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Curis, Inc. leads on 12 and AIM ImmunoTech Inc. on 5.

Valuation

Metric AIM CRIS Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 0.20 9.40
P/B 0.35 0.40 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 0.29 0.66
EV/Sales (71.38) (0.27) 9.02
Earnings yield (2,575.37%) (1,615.91%) (32.88%)
Free cash flow yield (533.84%) (1,649.45%) (23.13%)

Profitability

Metric AIM CRIS Biotechnology median
Gross margin (23.16%) 99.52% 68.51%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) 455.35% (51.96%)
Return on assets (169.28%) (87.76%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM CRIS Biotechnology median
Revenue growth (TTM) (21.49%) (13.43%) 6.76%
EPS growth (last fiscal year) 72.19% 91.57% 29.88%
Revenue growth, 5-year CAGR (11.60%) (2.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM CRIS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 0.49 4.97
Net debt to EBITDA 0.22 0.91 1.01

Dividend

Metric AIM CRIS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM CRIS Biotechnology median
Market cap 6.07m 5.67m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack